Welcome Daniela Sica, VP, Business Development, Pharma and Biotech

News
Published on:
December 15, 2020

BOSTON, USA – Alira Health, a leading international healthcare and life sciences advisory firm, is pleased to announce that Daniela Sica has joined the firm as Vice President, Business Development, Pharma and Biotech. Daniela has extensive experience in the pharmaceutical and biotech space, and is based out of Alira Health’s Barcelona, Spain office.

We are thrilled to welcome Daniela to the Alira Health Team,” said Benjamin Chambon, Chief Commercial Officer and EVP, Transaction Advisory. “Her notable experience in the pharma and biotech field will play a critical role in further enhancing the Alira Health lifecycle offering, and, in turn, continuing to improve synergies across our practice areas for the benefit of our clients.”
I have been following the evolution of Alira Health for several years, prior to joining the team,” said Daniela. “I have always admired the passion and commitment of the founders and leadership team, and the depth of expertise within the company. I am thrilled to join Alira Health at this exciting stage of its development.”

Daniela has over 25 years of management experience with pharmaceutical and biotech companies, and CDMOs. She has worked in business development, alliance management, and strategic planning with worldwide responsibilities, building a strong network of international relationships. Daniela has strong transaction experience, having led negotiations in co-development deals involving some of the largest global pharma companies.

Daniela sits on several biotech evaluation commissions, supporting biotech accelerators in their investment decisions. She has a degree in Food Science and Technology from the University of Milan, with a qualification as a Food Science Expert.

Learn more about our Team

Our Team

Related news

Events February 22, 2024
Bio-Europe Spring
Connect with our biotech experts onsite in Barcelona at Bio-Europe Spring. How can we support your development plan and funding path?
Biotech
Blog February 14, 2024
Biopharma in 2024: The Industry Outlook
Insights from recent J.P. Morgan Healthcare Conference including what's changed in biopharma since last year and what to expect this year.
Biopharma Biotech
News February 7, 2024
Alira Health Advises Aesculapius Farmaceutici Srl in Its Acquisition by Ceres Pharma NV
We are pleased to have represented as transaction advisor Aesculapius, a leading Italian pharmaceutical company active in the development and distribution of prescription drugs, OTC(...)
Pharma Transaction Advisory
Events February 1, 2024
2023 BioRegion Report Presentation
Biotech Spain
News January 26, 2024
Alira Health’s CDD Supports Alcami Acquisition of Pacific Pharmaceutical Services
We are pleased to have been an advisor on Alcami’s acquisition of Pacific Pharmaceutical Services (PPS). Alira Health advised Alcami, a leading Contract Development Manufacturing(...)
CDD CDMO Pharma
News January 24, 2024
Alira Health and AseBio Announce Market Access Mentoring Program for 2024
Alira Health and AseBio, the Spanish Bioindustry Association, are pleased to announce the 2024 edition of their market access mentoring program for AseBio members.
Biotech Market Access Spain Startups
Events January 22, 2024
Pharmapack Europe
Connect with our Drug Delivery Systems and CDMO experts Aude Ouensanga, Giulia Valsecchi, and Michal Raciborski on site at Pharmapack Europe.
CDMO Drug Delivery Pharma
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.